Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Role of the mitotic checkpoint in transformation of Brca2 null cells

Author: Michael Davies

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Brca2 is a tumour suppressor gene involved in some hereditary human breast cancers. The murine gene encodes a nuclear protein that binds to Rad51, implicating BRCA2 in DNA repair. Mice homozygous for truncated Brca2 are mostly nonviable; however, the few that do survive show severe growth retardation and develop thymic lymphomas. The murine embryonic cells homozygous for truncated Brca2show a severe proliferative defect and are more susceptible to X-rays and other genotoxins, despite normal enforcement of checkpoints activated by DNA damage. …
Literature
1.
Lee H, Trainer AH, Friedman LS, Thistlethwaite FC, Evans MJ, Ponder BAJ, Venkitaraman AR: Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell. 1999, 4: 1-10.CrossRefPubMed
Metadata
Title
Role of the mitotic checkpoint in transformation of Brca2 null cells
Author
Michael Davies
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66606

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue

Review

The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives

Review

The pathology of familial breast cancer: Immunohistochemistry and molecular analysis

Paper Report

BRCA2overexpression in breast cancer

Paper Report

Visibility of cancer on earlier mammograms in the Finnish breast screening programme

Paper Report

Risk of breast cancer in women with palpable breast cysts

Paper Report

Interaction of BRCA1 and AR genes in breast cancer risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits